A Multicenter, Randomized, Double-Blind and Open-label Phase III Study To Compare The Efficacy And Safety Of Eltrombopag With Placebo In Chinese Chronic ITP Patients.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Eltrombopag (Primary)
- Indications Hepatitis C; Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis; Novartis Pharmaceuticals
- 23 May 2017 Planned End Date changed from 1 Jul 2017 to 31 Jan 2018.
- 30 Apr 2015 New trial record